Indeed, safety and efficacy of AAV-delivered gene therapies in animal studies have aided the progression of a number of such therapies into clinical trials (ClinicalTrials.gov); Luxturna for biallelic RPE65 IRDs (FDA/EMA approvals in 2017–2018), RPGR and PDE6B supplementation for corresponding forms of RP, RS1 supplementation for retinoschisis or REP1 supplementation for choroideremia (ClinicalTrials.gov). Here, RPGR is linked to retinoschisis.